nach oben

Clinical Rheumatology

Erschienen in:

03.04.2018 | Original Article

Resveratrol as an effective adjuvant therapy in the management of rheumatoid arthritis: a clinical study

verfasst von: Hani M. Khojah, Sameh Ahmed, Mahran S. Abdel-Rahman, Eman H. Elhakeim

Erschienen in: Clinical Rheumatology | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Abstract

Resveratrol (RSV), a naturally occurring polyphenol, has been found to have potent antioxidant, anti-inflammatory, and anticancer effects. Recently, RSV was reported as a new potential agent to suppress inflammation of collagen-induced arthritis in a mouse model. Nevertheless, the clinical benefits of RSV in the management of rheumatoid arthritis (RA) were not studied. This randomized controlled clinical trial aims to shed some light on the therapeutic benefits of RSV in the treatment of RA in patients with different stages of the disease activity. In this randomized controlled clinical trial, 100 RA patients (68 female, 32 male) were enrolled randomly and divided into two groups, each of 50 patients: an RSV-treated group that received a daily RSV capsule of 1 g with the conventional treatment for 3 months and a control group that just received the regular treatment. The clinical and biochemical markers of RA in both groups were assessed. It was found that the clinical markers (i.e., the 28-joint count for swelling and tenderness) and the disease activity score assessment for 28 joints were significantly lowered in the RSV-treated group. Moreover, serum levels of certain biochemical markers (i.e., C-reactive protein, erythrocyte sedimentation rate, undercarboxylated osteocalcin, matrix metalloproteinase-3, tumor necrosis factor alpha, and interleukin-6) were also significantly decreased in RSV-treated patients. The current study suggests the addition of RSV as an adjuvant to the conventional antirheumatic drugs.

Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423(6937):356–361. https://doi.org/10.1038/nature01661 CrossRefPubMed

Choy E (2012) Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 51:v3–v11. https://doi.org/10.1093/rheumatology/kes113

Saxne T, Palladino MA Jr, Heinegard D, Talal N, Wollheim FA (1988) Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 31(8):1041–1045CrossRefPubMed

Olsen NJ, Stein CM (2004) New drugs for rheumatoid arthritis. N Engl J Med 350(21):2167–2179. https://doi.org/10.1056/NEJMra032906 CrossRefPubMed

Walle T (2011) Bioavailability of resveratrol. Ann N Y Acad Sci 1215:9–15. https://doi.org/10.1111/j.1749-6632.2010.05842.x CrossRefPubMed

Elliott PJ, Jirousek M (2008) Sirtuins: novel targets for metabolic disease. Curr Opin Investig Drugs 9(4):371–378PubMed

Yoo S-J, Go E, Kim Y-E, Lee S, Kwon J (2016) Roles of reactive oxygen species in rheumatoid arthritis pathogenesis. J Rheum Dis 23(6):340–347CrossRef

Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE (2009) Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer’s disease. Neurochem Int 54(2):111–118. https://doi.org/10.1016/j.neuint.2008.10.008 CrossRefPubMed

Elmali N, Baysal O, Harma A, Esenkaya I, Mizrak B (2007) Effects of resveratrol in inflammatory arthritis. Inflammation 30(1–2):1–6. https://doi.org/10.1007/s10753-006-9012-0 CrossRefPubMed

10.

Nakayama H, Yaguchi T, Yoshiya S, Nishizaki T (2012) Resveratrol induces apoptosis MH7A human rheumatoid arthritis synovial cells in a sirtuin 1-dependent manner. Rheumatol Int 32(1):151–157. https://doi.org/10.1007/s00296-010-1598-8 CrossRefPubMed

11.

Yun-Hong C, Hyun-Ok K, Young-Sun S, Jae Hyung H, Wonyong J, Hye-Song L, Young-Sool H, Mi Jeong S, Dae Young K, Sang-Il L (2015) Inhibitory effects for rheumatoid arthritis of dietary supplementation with resveratrol in collagen-induced arthritis. J Rheum Dis 22(2):93–101CrossRef

12.

Byun HS, Song JK, Kim YR, Piao L, Won M, Park KA, Choi BL, Lee H, Hong JH, Park J, Seok JH, Lee YJ, Kang SW, Hur GM (2008) Caspase-8 has an essential role in resveratrol-induced apoptosis of rheumatoid fibroblast-like synoviocytes. Rheumatology (Oxford) 47(3):301–308. https://doi.org/10.1093/rheumatology/kem368 CrossRef

13.

Xuzhu G, Komai-Koma M, Leung BP, Howe HS, McSharry C, McInnes IB, Xu D (2012) Resveratrol modulates murine collagen-induced arthritis by inhibiting Th17 and B-cell function. Ann Rheum Dis 71(1):129–135. https://doi.org/10.1136/ard.2011.149831 CrossRefPubMed

14.

Almeida L, Vaz-da-Silva M, Falcao A, Soares E, Costa R, Loureiro AI, Fernandes-Lopes C, Rocha JF, Nunes T, Wright L, Soares-da-Silva P (2009) Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res 53:S7–S15. https://doi.org/10.1002/mnfr.200800177

15.

Cottart CH, Nivet-Antoine V, Laguillier-Morizot C, Beaudeux JL (2010) Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res 54(1):7–16. https://doi.org/10.1002/mnfr.200900437 CrossRefPubMed

16.

Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324CrossRefPubMed

17.

Anton SD, Embry C, Marsiske M, Lu X, Doss H, Leeuwenburgh C, Manini TM (2014) Safety and metabolic outcomes of resveratrol supplementation in older adults: results of a twelve-week, placebo-controlled pilot study. Exp Gerontol 57:181–187. https://doi.org/10.1016/j.exger.2014.05.015 CrossRefPubMed

18.

Efsa Panel on Dietetic Products N, Allergies (2016) Safety of synthetic trans-resveratrol as a novel food pursuant to Regulation (EC) No 258/97. EFSA J 14(1):4368–4397. https://doi.org/10.2903/j.efsa.2016.4368 CrossRef

19.

Novelle MG, Wahl D, Dieguez C, Bernier M, de Cabo R (2015) Resveratrol supplementation: where are we now and where should we go? Ageing Res Rev 21:1–15. https://doi.org/10.1016/j.arr.2015.01.002 CrossRefPubMedPubMedCentral

20.

Singh G, Pai RS (2014) A rapid reversed-phase HPLC method for analysis of trans-resveratrol in PLGA nanoparticulate formulation. ISRN Chromatography 2014:6. https://doi.org/10.1155/2014/248635 CrossRef

21.

Sokoll LJ, O’Brien ME, Camilo ME, Sadowski JA (1995) Undercarboxylated osteocalcin and development of a method to determine vitamin K status. Clin Chem 41(8 Pt 1):1121–1128PubMed

22.

Obata K, Iwata K, Okada Y, Kohrin Y, Ohuchi E, Yoshida S, Shinmei M, Hayakawa T (1992) A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 3 (stromelysin-1) using monoclonal antibodies. Clin Chim Acta 211(1–2):59–72CrossRefPubMed

23.

Tas F, Oguz H, Argon A, Duranyildiz D, Camlica H, Yasasever V, Topuz E (2005) The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma: serum IL-6 level is a valuable prognostic factor at least as serum LDH in advanced melanoma. Med Oncol 22(3):241–246. https://doi.org/10.1385/mo:22:3:241 CrossRefPubMed

24.

Matsui T, Kuga Y, Kaneko A, Nishino J, Eto Y, Chiba N, Yasuda M, Saisho K, Shimada K, Tohma S (2007) Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan. Ann Rheum Dis 66(9):1221–1226. https://doi.org/10.1136/ard.2006.063834 CrossRefPubMedPubMedCentral

25.

Abdel-Rahman MS, Alkady EA, Ahmed S (2015) Menaquinone-7 as a novel pharmacological therapy in the treatment of rheumatoid arthritis: a clinical study. Eur J Pharmacol 761:273–278. https://doi.org/10.1016/j.ejphar.2015.06.014 CrossRefPubMed

26.

Fransen J, van Riel PL (2005) The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 23:S93–S99PubMed

27.

Berman AY, Motechin RA, Wiesenfeld MY, Holz MK (2017) The therapeutic potential of resveratrol: a review of clinical trials. NPJ Precis Oncol 1:35. https://doi.org/10.1038/s41698-017-0038-6 CrossRefPubMedPubMedCentral

28.

Wahab A, Gao K, Jia C, Zhang F, Tian G, Murtaza G, Chen J (2017) Significance of resveratrol in clinical management of chronic diseases. Molecules 22(8). https://doi.org/10.3390/molecules22081329

29.

Theodotou M, Fokianos K, Mouzouridou A, Konstantinou C, Aristotelous A, Prodromou D, Chrysikou A (2017) The effect of resveratrol on hypertension: a clinical trial. Exp Ther Med 13(1):295–301. https://doi.org/10.3892/etm.2016.3958 CrossRefPubMed

30.

Ozturk E, Arslan AKK, Yerer MB, Bishayee A (2017) Resveratrol and diabetes: a critical review of clinical studies. Biomed Pharmacother 95:230–234. https://doi.org/10.1016/j.biopha.2017.08.070 CrossRefPubMed

31.

Haghighatdoost F, Hariri M (2018) Effect of resveratrol on lipid profile: an updated systematic review and meta-analysis on randomized clinical trials. Pharmacol Res 129:141–150. https://doi.org/10.1016/j.phrs.2017.12.033 CrossRefPubMed

32.

Qiang L, Di Y, Jiang Z, Xu J (2017) Resveratrol improves efficacy of oral amoxicillin against childhood fast breathing pneumonia in a randomized placebo-controlled double blind clinical trial. Microb Pathog 114:209–212. https://doi.org/10.1016/j.micpath.2017.11.062 CrossRefPubMed

33.

Mendes da Silva D, Gross LA, Neto EPG, Lessey BA, Savaris RF (2017) The use of resveratrol as an adjuvant treatment of pain in endometriosis: a randomized clinical trial. J Endocr Soc 1(4):359–369. https://doi.org/10.1210/js.2017-00053 CrossRefPubMedPubMedCentral

34.

Heeboll S, Kreuzfeldt M, Hamilton-Dutoit S, Kjaer Poulsen M, Stodkilde-Jorgensen H, Moller HJ, Jessen N, Thorsen K, Kristina Hellberg Y, Bonlokke Pedersen S, Gronbaek H (2016) Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand J Gastroenterol 51(4):456–464. https://doi.org/10.3109/00365521.2015.1107620 CrossRefPubMed

35.

McDermott MM, Leeuwenburgh C, Guralnik JM, Tian L, Sufit R, Zhao L, Criqui MH, Kibbe MR, Stein JH, Lloyd-Jones D, Anton SD, Polonsky TS, Gao Y, de Cabo R, Ferrucci L (2017) Effect of resveratrol on walking performance in older people with peripheral artery disease: the RESTORE randomized clinical trial. JAMA Cardiol 2(8):902–907. https://doi.org/10.1001/jamacardio.2017.0538 CrossRefPubMedPubMedCentral

36.

McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, Capell HA, Sattar N (2004) Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363(9426):2015–2021. https://doi.org/10.1016/s0140-6736(04)16449-0 CrossRefPubMed

37.

Di Giuseppe D, Alfredsson L, Bottai M, Askling J, Wolk A (2012) Long term alcohol intake and risk of rheumatoid arthritis in women: a population based cohort study. BMJ 345:e4230. https://doi.org/10.1136/bmj.e4230 CrossRefPubMedPubMedCentral

38.

Manicourt DH, Triki R, Fukuda K, Devogelaer JP, Nagant de Deuxchaisnes C, Thonar EJ (1993) Levels of circulating tumor necrosis factor alpha and interleukin-6 in patients with rheumatoid arthritis. Relationship to serum levels of hyaluronan and antigenic keratan sulfate. Arthritis Rheum 36(4):490–499CrossRefPubMed

39.

Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, Vasilinin G, Sen A, Schinas AM, Piccirilli G, Brown K, Steward WP, Gescher AJ, Brenner DE (2010) Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 70(22):9003–9011. https://doi.org/10.1158/0008-5472.can-10-2364 CrossRefPubMedPubMedCentral

Titel: Resveratrol as an effective adjuvant therapy in the management of rheumatoid arthritis: a clinical study
verfasst von: Hani M. Khojah
Sameh Ahmed
Mahran S. Abdel-Rahman
Eman H. Elhakeim
Publikationsdatum: 03.04.2018
Verlag: Springer London
Erschienen in: Clinical Rheumatology / Ausgabe 8/2018
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-018-4080-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Resveratrol as an effective adjuvant therapy in the management of rheumatoid arthritis: a clinical study

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2018

Birmingham vasculitis activity and chest manifestation at diagnosis can predict hospitalised infection in ANCA-associated vasculitis

Influence of autoimmunity and inflammation on endothelial function and thrombosis in systemic lupus erythematosus patients

Assessment of aortic stiffness in patients with ankylosing spondylitis using cardiovascular magnetic resonance

The first case of bacillus Calmette-Guérin-induced small-vessel central nervous system vasculitis

Differences in daily objective physical activity and sedentary time between women with self-reported fibromyalgia and controls: results from the Canadian health measures survey

Late restoration of renal function in patients with severe ANCA-associated glomerulonephritis who were dialysis-dependent at presentation

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin